NCT04302103 is a Phase 2 clinical trial of RC18 160mg in Systemic Myasthenia Gravis, sponsored by RemeGen Co., Ltd..

Who is sponsoring NCT04302103?

NCT04302103 is sponsored by RemeGen Co., Ltd..

What drugs are being tested in NCT04302103?

Interventions in NCT04302103: RC18 160mg, RC18 240 mg.

What condition does NCT04302103 study?

NCT04302103 studies Systemic Myasthenia Gravis.

Is NCT04302103 still recruiting?

NCT04302103 is currently completed. Last updated 11 October 2023.

Last reviewed 2023-10-11 · How we verify

NCT04302103

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis

Completed Phase 2 Last updated 11 October 2023

What this trial tests

Phase 2 trial testing RC18 160mg in Systemic Myasthenia Gravis in 29 participants. Completed in 11 February 2022.

Timeline

7 July 2020

Primary endpoint
14 January 2022

11 February 2022

Quick facts

Lead sponsor	RemeGen Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	7 July 2020
Primary completion	14 January 2022
Estimated completion	11 February 2022
Sites	1 location across China

Drugs / interventions tested

RC18 160mg — full drug profile →
RC18 240 mg — full drug profile →

Conditions studied

Systemic Myasthenia Gravis — all drugs for Systemic Myasthenia Gravis →

Sponsor

RemeGen Co., Ltd. — full company profile →

Who can join

Adults 18 to 70, any sex, with Systemic Myasthenia Gravis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with systemic myasthenia gravis.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

B cell depletion therapies in autoimmune disease: advances and mechanistic insights.
Lee DSW, Rojas OL, Gommerman JL. · · 2021 · cited 496× · PMID 33324003 · DOI 10.1038/s41573-020-00092-2
Advances and challenges in the treatment of myasthenia gravis.
Schneider-Gold C, Gilhus NE. · · 2021 · cited 40× · PMID 34987614 · DOI 10.1177/17562864211065406
Novel Immunotherapies for Myasthenia Gravis.
Nair SS, Jacob S. · · 2023 · cited 38× · PMID 37038596 · DOI 10.2147/itt.s377056
A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis.
Yin J, Zhao M, Xu X, Zhang M, et al · · 2024 · cited 33× · PMID 38726639 · DOI 10.1111/ene.16322
Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
Vakrakou AG, Karachaliou E, Chroni E, Zouvelou V, et al · · 2023 · cited 33× · PMID 37564637 · DOI 10.3389/fimmu.2023.1212757
Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single-center, single-arm, open-label study.
Ding J, Jiang X, Cai Y, Pan S, et al · · 2022 · cited 31× · PMID 35851754 · DOI 10.1111/cns.13904
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making.
Gerischer L, Doksani P, Hoffmann S, Meisel A. · · 2025 · cited 18× · PMID 39869260 · DOI 10.1007/s40259-024-00701-1
Treating myasthenia gravis beyond the eye clinic.
Jacob S. · · 2024 · cited 9× · PMID 38789789 · DOI 10.1038/s41433-024-03133-x

Verify or expand the search:

Other trials of RC18 160mg

Trials testing the same drug.

NCT04625153 — RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial · Phase 2 · terminated
NCT04291781 — A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy · Phase 2 · completed

Other RemeGen Co., Ltd. trials

Trials by the same sponsor.

NCT07537881 — A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07462143 — A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT07495033 — Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related I · Phase 3 · not yet recruiting
NCT07416474 — RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Smal · Phase 3 · not yet recruiting
NCT07249632 — A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04302103 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RemeGen Co., Ltd.
Last refreshed: 11 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04302103.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing